Guus Scheefhals
Directeur Général chez Crossbeta Biosciences BV
Profil
Guus Scheefhals currently works at Crossbeta Biosciences BV, as Chief Executive Officer from 2010.
Mr. Scheefhals also formerly worked at DegenRx BV, as Chief Executive Officer from 2018 to 2020, Avantium Technologies BV, as Chief Business Officer from 2003 to 2010, and DSM Biologics Holding, Inc., as Manager-Business Development.
Mr. Scheefhals received his graduate degree from the University of Utrecht.
Postes actifs de Guus Scheefhals
| Sociétés | Poste | Début |
|---|---|---|
Crossbeta Biosciences BV
 Crossbeta Biosciences BV BiotechnologyHealth Technology Crossbeta Biosciences BV develops drug discovery programs in the area of misfolded protein diseases. It specializes in alzheimer's disease drug development and drug discovery platform services. The company was founded by Martijn Gebbink and Barend Bouma in 2005 and is headquartered in Utrecht, the Netherlands. | Directeur Général | 15/04/2010 |
Anciens postes connus de Guus Scheefhals
| Sociétés | Poste | Fin |
|---|---|---|
DegenRx BV
 DegenRx BV BiotechnologyHealth Technology DegenRx BV is a Dutch biotech company that is focused on developing AAV-mediated gene therapy for the treatment of CNS diseases such as Alzheimer's and Parkinson's disease. The company is based in Tilburg, Netherlands. The company aims to address the lack of drugs available to stop or slow down the progression of Alzheimer's disease, which affects about two-thirds of the 50 million people reported to suffer from dementia worldwide. One of the approaches most advanced in clinical studies is immunotherapy against amyloid beta, which DegenRx is working on. Inez de Greef-van der Sand has been the CEO of the company since 2020. | Directeur Général | 01/09/2020 |
DSM Biologics Holding, Inc.
 DSM Biologics Holding, Inc. BiotechnologyHealth Technology Part of DSM BV, DSM Biologics Holding, Inc. is a Canadian company that manufactures biological and pharmaceutical products. The company is based in Montréal, Canada. The company was founded by Jos van Weperen. DSM Biologics Holding was acquired by DSM Pharmaceuticals, Inc., a subsidiary of DSM BV from Province of Québec on July 13, 2005. | Corporate Officer/Principal | - |
Avantium Technologies BV
 Avantium Technologies BV Miscellaneous Commercial ServicesCommercial Services Avantium Technologies BV operates as chemical technology company. It offers a breeding ground for revolutionary renewable chemistry solutions. The firm specializes in innovations and technologies for catalytic research and development services and systems. The company was founded in February 2000 and is headquartered in Amsterdam, the Netherlands | Directeur des opérations | - |
Formation de Guus Scheefhals
| University of Utrecht | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
Avantium Technologies BV
Avantium Technologies BV Miscellaneous Commercial ServicesCommercial Services Avantium Technologies BV operates as chemical technology company. It offers a breeding ground for revolutionary renewable chemistry solutions. The firm specializes in innovations and technologies for catalytic research and development services and systems. The company was founded in February 2000 and is headquartered in Amsterdam, the Netherlands | Commercial Services |
DSM Biologics Holding, Inc.
DSM Biologics Holding, Inc. BiotechnologyHealth Technology Part of DSM BV, DSM Biologics Holding, Inc. is a Canadian company that manufactures biological and pharmaceutical products. The company is based in Montréal, Canada. The company was founded by Jos van Weperen. DSM Biologics Holding was acquired by DSM Pharmaceuticals, Inc., a subsidiary of DSM BV from Province of Québec on July 13, 2005. | Health Technology |
Crossbeta Biosciences BV
Crossbeta Biosciences BV BiotechnologyHealth Technology Crossbeta Biosciences BV develops drug discovery programs in the area of misfolded protein diseases. It specializes in alzheimer's disease drug development and drug discovery platform services. The company was founded by Martijn Gebbink and Barend Bouma in 2005 and is headquartered in Utrecht, the Netherlands. | Health Technology |
DegenRx BV
DegenRx BV BiotechnologyHealth Technology DegenRx BV is a Dutch biotech company that is focused on developing AAV-mediated gene therapy for the treatment of CNS diseases such as Alzheimer's and Parkinson's disease. The company is based in Tilburg, Netherlands. The company aims to address the lack of drugs available to stop or slow down the progression of Alzheimer's disease, which affects about two-thirds of the 50 million people reported to suffer from dementia worldwide. One of the approaches most advanced in clinical studies is immunotherapy against amyloid beta, which DegenRx is working on. Inez de Greef-van der Sand has been the CEO of the company since 2020. | Health Technology |
